36. 下列有關 Tamoxifen 的敘述,何者正確?
(A) 是一種雄性激素受體拮抗劑
(B) 用於治療不孕症
(C) 為類固醇結構,不可口服使用
(D) 半衰期較 Estradiol 長
答案:登入後查看
統計:
A(5), B(3), C(2), D(11), E(0) #510331
詳解 (共 1 筆)
| 結構式 | |

|
| 藥理作用 | |
本品為雄性激素衍生物,主要做為乳癌之治療及乳癌手術後之輔助療法。 以 triphenylethylene 為基礎之非類固醇藥物,其作用機轉為與雌素接受體結合,進而抑制內生性 estrogen 作用抗雌激素劑作用,避免雌激素與雌激素接受體結合。
|
| 適應症 | |
| 轉移性乳癌之治療、乳癌手術後之輔助療法。 |
| 用法用量 | |
每天20~40mg,可分為一天兩次給藥,或一天一次給藥。
| 藥動力學 | | Absorption:Tamoxifen C max is 40 ng/mL (range, 35 to 45 ng/mL), T max is approximately 5 h after dosing, and steady state is achieved in about 4 wk. Metabolism:Tamoxifen is extensively metabolized. The major metabolite is N-desmethyl tamoxifen. It is a substrate of CYP450 3A, 2C9, 2D6, and an inhibitor of P-glycoprotein. Elimination:Tamoxifen t ½ is 5 to 7 days; 65% of a dose is excreted over a 2-wk period, with fecal excretion as the primary route of elimination. | 交互作用 | | Aminoglutethimide, phenobarbital :Tamoxifen concentrations may be reduced. Anastrozole :Plasma concentrations of anastrozole may be decreased. Do not coadminister. Bromocriptine :Tamoxifen concentrations may be increased. Cytotoxic agents :Increased risk of thromboembolic events. Letrozole :Plasma concentrations may be decreased by tamoxifen, reducing the therapeutic effect. Rifamycins (eg, rifampin) :Tamoxifen plasma levels may be reduced, decreasing the antiestrogenic effect. Warfarin :Increased hypoprothrombinemic effect.
| | 禁忌 | | 孕婦不得服用,婦女在服用estrogen receptor antagonist轉移性本品時或停藥後兩個月議不要受孕。
| | 注意事項 | | | 部分停經前之婦女使用本藥品治療乳癌腫瘤時,月經會受到抑制。 | | 藥品保存方式 | | | 藥品應置於攝氏 15 ~ 25 度乾燥處所;如發生變質或過期,不可再食用。 |
|
|